United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(X) Quarterly Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
For the quarterly period ended June 30, 1997
or
( ) Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
For the transition period from ______ to ______
Commission File Number 33-14582
PAINEWEBBER R&D PARTNERS II, L.P.
(Exact name of registrant as specified in its charter)
Delaware 13-3437420
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1285 Avenue of the Americas, New York, New York 10019
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (212) 713-2000
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] [No]
SPECIAL NOTE REGARDING
FORWARD LOOKING STATEMENTS
The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Except for the historical information
contained herein, the matters discussed herein are forward-looking statements.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or achievements
of PaineWebber R&D Partners II, L.P. or industry results to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions; fluctuations in the
value of securities for which only a limited, or no, public market exists;
dependence on the development of new technologies; dependence on timely
development and introduction of new and competitively priced products; the need
for regulatory approvals; the Sponsor Companies (hereinafter defined) having
insufficient funds to commercialize products to their maximum potential; the
restructuring of Sponsor Companies; the dependence of PaineWebber R&D Partners
II, L.P. on the skills of certain scientific personnel; and the dependence of
the Partnership on the General Partner (hereinafter defined).
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Form 10-Q
June 30, 1997
Table of Contents
PART I. FINANCIAL INFORMATION Page
Item 1. Financial Statements
Statements of Financial Condition (unaudited) 2
at June 30, 1997 and December 31, 1996
Statements of Operations
(unaudited) for the three months and six months
ended June 30, 1997 and 1996 3
Statement of Changes in Partners' Capital
(unaudited) for the six months ended
June 30, 1997 4
Statements of Cash Flows
(unaudited) for the six months ended
June 30, 1997 and 1996 5
Notes to Financial Statements
(unaudited) 6-12
Item 2. Management's Discussion and Analysis of Financial 13-14
Condition and Results of Operations
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 15-16
Item 6. Exhibits and Reports on Form 8-K 16
Signatures 17
All schedules are omitted either because they are not applicable or the
information required to be submitted has been included in the financial
statements or notes thereto.
Item 1. Financial Statements
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Financial Condition
(unaudited)
June 30, December 31,
1997 1996
------------- --------------
Assets:
Cash $ 6,998 $ 5,028
Marketable securities, at market value 1,139,796 899,197
Investments, at fair value 1,874,252 1,633,000
Due from product development project 900,000 --
Advances to product development projects -- 135,519
Royalty income receivable 6,600 774,834
------------- --------------
Total assets $ 3,927,646 $ 3,447,578
============= ==============
Liabilities and partners' capital:
Due to product development project $ -- $ 297,000
Accrued liabilities 75,725 97,188
Partners' capital 3,851,921 3,053,390
----------- ------------
Total liabilities and partners' capital $ 3,927,646 $ 3,447,578
============ =============
See notes to financial statements.
2
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Operations
(unaudited)
For the three months ended June 30, 1997 1996
----------- -----------
Revenues:
Interest income $ 21,351 $ 9,118
Income from product development projects 693,322 176,735
Unrealized appreciation (depreciation) of
investments and marketable securities 925,950 (1,520,000)
Realized loss on sale of investments and
marketable securities -- (44,094)
----------- -----------
1,640,623 (1,378,241)
----------- -----------
Expenses:
Management fee -- 68,505
General and administrative costs 44,887 41,519
----------- -----------
44,887 110,024
----------- -----------
Net income (loss) $ 1,595,736 $(1,488,265)
=========== ===========
Net income (loss) per partnership unit:
Limited partners (based on 8,257 units) $ 191.33 $ (178.44)
General partner $ 15,957.36 $(14,882.65)
For the six months ended June 30, 1997 1996
----------- -----------
Revenues:
Interest income $ 56,322 $ 21,111
Income from product development projects 5,053,100 205,487
Unrealized appreciation (depreciation) of
investments and marketable securities 688,127 (1,955,300)
Realized gain (loss) on sale of investments and
marketable securities 540,000 (53,421)
----------- -----------
6,337,549 (1,782,123)
----------- -----------
Expenses:
Expenditures under product development
projects 20,483 --
Management fee -- 137,010
General and administrative costs 97,273 103,328
---------- ----------
117,756 240,338
---------- ----------
Net income (loss) $ 6,219,793 (2,022,461)
========== ===========
Net income (loss) per partnership unit:
Limited partners (based on 8,257 units) $ 745.74 $ (242.49)
General partner $ 62,197.93 $(20,224.61)
See notes to financial statements.
3
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statement of Changes in Partners' Capital
(unaudited)
Limited General
For the six months ended June 30, 1997 Partners Partner Total
---------- ---------- -----------
Balance at January 1, 1997 $ 3,018,776 $ 34,614 $ 3,053,390
Net income 6,157,595 62,198 6,219,793
Cash distribution to partners (5,367,050) (54,212) (5,421,262)
=========== =========== ===========
Balance at June 30, 1997 $ 3,809,321 $ 42,600 $ 3,851,921
=========== =========== ===========
See notes to financial statements.
4
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
Statements of Cash Flows
(unaudited)
For the six months ended June 30, 1997 1996
----------- -----------
Cash flows from operating activities:
Net income (loss) $ 6,219,793 $(2,022,461)
Adjustments to reconcile net income (loss) to cash
provided by (used for) operating activities:
Unrealized (appreciation) depreciation of
investments and marketable securities (688,127) 1,955,300
Expenditures under product development projects 20,483 --
(Increase) decrease in operating assets:
Marketable securities (253,724) (13,106)
Investments 460,000 49,126
Due from product development project (900,000) --
Interest receivable -- 5,518
Advances to product development projects 115,036 23,290
Royalty income receivable 768,234 10,455
Decrease in operating liabilities:
Due to product development project (297,000) --
Accrued liabilities (21,463) (9,428)
----------- -----------
Cash provided by (used for) operating activities 5,423,232 (1,306)
----------- -----------
Cash flows from financing activities:
Distributions to partners (5,421,262) --
----------- -----------
Increase (decrease) in cash 1,970 (1,306)
Cash at beginning of period 5,028 5,858
----------- -----------
Cash at end of period $ 6,998 $ 4,552
=========== ===========
Supplemental disclosure of cash flow information:
The Partnership paid no cash for interest or taxes during the six months ended
June 30, 1997 and 1996.
See notes to financial statements.
5
PAINEWEBBER R&D PARTNERS II, L.P.
(a Delaware Limited Partnership)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)
17
1. Organization and Business
The financial information as of and for the periods ended June 30, 1997
and 1996 is unaudited. However, in the opinion of management of PaineWebber R&D
Partners II, L.P. (the "Partnership"), such information includes all
adjustments, consisting only of normal recurring accruals, necessary for a fair
presentation. The results of operations reported for the interim periods ended
June 30, 1997, are not necessarily indicative of results to be expected for the
year ended December 31, 1997. These financial statements should be read in
conjunction with the most recent annual report of the Partnership on Form 10-K
for the year ended December 31, 1996, and the previously issued quarterly report
on Form 10-Q for the quarter ended March 31, 1997.
The Partnership is a Delaware limited partnership that commenced
operations on September 30, 1987 with a total of $72.0 million available for
investment. PWDC Holding Company (the "Manager") is the general partner of
PaineWebber Technologies II, L.P. (the "General Partner"), which is the general
partner of the Partnership. PWDC Holding Company is a wholly owned subsidiary of
Paine Webber Development Corporation ("PWDC"), an indirect, wholly owned
subsidiary of Paine Webber Group Inc. ("PWG"). The Partnership will terminate on
December 31, 2012, unless its term is extended or reduced by the General
Partner.
The principal objective of the Partnership is to provide long-term capital
appreciation to investors through investing in the development and
commercialization of new products with technology companies ("Sponsor
Companies"), which are expected to address significant market opportunities.
Once the product development phase is completed, the Sponsor Companies have the
option to license and commercialize the products resulting from the product
development project, and the Partnership has the right to receive payments based
upon the sale of such products. In connection with product development projects
(the "Projects"), the Partnership obtained warrants to purchase the common stock
of Sponsor Companies. These warrants have the potential to provide additional
capital appreciation to the Partnership which is not directly dependent upon the
outcome of the Projects (see Note 5). In addition, the Partnership invested as a
limited partner in product development limited partnerships. Such partnerships
were formed to develop specific, new products through contracts with Sponsor
Companies. The Sponsor Companies conduct the Projects and affiliates of the
Sponsor Companies serve as general partners of the partnerships. As such, the
Partnership has been engaged in diverse Projects including product development
contracts, participation in other partnerships and investments in securities of
the Sponsor Companies.
6
(Note 1 Continued)
All distributions to the limited partners of the Partnership (the "Limited
Partners") and the General Partner (collectively, the "Partners") from the
Partnership have been made pro rata in accordance with their respective net
capital contributions. The following table sets forth the proportion of each
distribution to be received by the Limited Partners and the General Partner,
respectively:
Limited General
Partners Partners
-------- --------
I. Until the value of the aggregate distributions for each limited partnership
unit ("Unit") equals $10,000 plus simple interest on such amount accrued at
7% per annum for each Unit sold at the Initial Closing (6% per annum for
each subsequent Unit sold up to the 5,000th Unit and 5% per annum for each
Unit sold thereafter) ("Contribution Payout")................................. 99% 1%
II. After Contribution Payout and until the value of the aggregate
distributions for each Unit equals $50,000 ("Final Payout")................... 80% 20%
III. After Final Payout............................................................ 75% 25%
For the six months ended June 30, 1997, the Partnership made cash
distributions totaling $5,421,262 ($650 per Unit; $54,212 to the General
Partner). At June 30, 1997, the Partnership has made cash and security
distributions, as valued on the dates of distribution, since inception of $2,516
and $7,206 per Unit, respectively.
Effective December 10, 1996, the General Partner discontinued the right of
Limited Partners to transfer Units except for transfers that may occur as of the
result of the laws of descent and distribution and by operation of law (see note
8 - Subsequent Events).
2. Summary of Significant Accounting Policies
The financial statements are prepared in conformity with generally
accepted accounting principles which require management to make certain
estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from those
estimates.
Marketable securities consist of a money market fund and common stock
which are recorded at market value. Marketable securities are not considered
cash equivalents for the Statements of Cash Flows.
Realized and unrealized gains or losses are determined on a specific
identification method and are reflected in the Statements of Operations during
the period in which the change in value occurs.
7
(Note 2 Continued)
The Partnership invests in product development contracts with Sponsor
Companies either directly or through product development limited partnerships.
The Partnership expenses product development costs when incurred by the Sponsor
Companies and such costs are reflected as expenditures under product development
projects in the accompanying Statements of Operations. Income received and/or
accrued from investments in Projects is reflected in the Statements of
Operations for the period in which the income is earned.
The Partnership carries warrants at a zero value in cases where the
Sponsor Company's stock is not publicly traded or the exercise period has not
been attained. To the extent that the Partnership's warrants are currently
exercisable and the Sponsor Company's stock is publicly traded, the warrants are
carried at intrinsic value (the excess of market price per share over the
exercise price per share), which approximates fair value.
3. Marketable Securities and Investments
Marketable Securities:
The Partnership held the following marketable securities:
June 30, 1997 December 31, 1996
----------------------------- ----------------------------
Market Cost Market Cost
----------- ----------- ----------- -----------
Money market fund $ 1,052,821 $ 1,052,821 $ 799,097 $ 799,097
Centocor, Inc. common stock (2,800 shares) 86,975 37,324 100,100 37,324
----------- ----------- ----------- -----------
$ 1,139,796 $ 1,090,145 $ 899,197 $ 836,421
=========== ============ =========== ===========
In June 1996, the Partnership sold 11,867 shares of Cygnus, Inc.
("Cygnus") with carrying values as of March 31, 1996 and December 31, 1995 of
$247,724 ($20.875 per share) and $265,525 ($22.375 per share), respectively.
Proceeds, net of commissions, were $203,630 resulting in a loss upon the sale
for the three months and six months ended June 30, 1996 of $44,094 and $61,895,
respectively. In February 1996, the Partnership exercised its warrant to
purchase 2,800 common shares of Centocor, Inc. ("Centocor") at an exercise price
of $37,324 ($13.33 per share). At June 30, 1997, Centocor common stock had a
market value of $31.0625 per share as compared to $35.75 per share at December
31, 1996. Accordingly, the Partnership recognized unrealized depreciation of
$13,125 for the six months ended June 30, 1997.
8
(Note 3 Continued)
Investments:
The Partnership held the following investments:
June 30, 1997 December 31, 1996
------------- -----------------
Cygnus, Inc.
Warrant to purchase: 255,000 common shares $ 1,874,252 $ 1,173,000
OEC Medical Systems, Inc.
Warrant to purchase: 200,000 common shares --- 460,000
----------- -----------
$ 1,874,252 $ 1,633,000
=========== ===========
The Partnership records its warrant to purchase common shares of Cygnus
(with an exercise price of $9.90 per share) as an investment with a carrying
value equal to its intrinsic value (which approximates fair value) -- (see Note
5). The market value of Cygnus stock as of June 30, 1997, was $17.25 per share
as compared to a market value of $13.625 and $14.50 per share as of March 31,
1997 and December 31, 1996, respectively. Accordingly, the Partnership
recognized unrealized appreciation on its warrant to purchase 255,000 Cygnus
shares of $924,375 and $701,252 for the three months and six months ended June
30, 1997, respectively. At December 31, 1996, the market value of OEC Medical
Systems, Inc. ("OEC") stock of $15.00 per share exceeded the exercise price of
the warrant of $12.70 per share. The Partnership recorded its investment in a
warrant to purchase 200,000 OEC shares at its intrinsic value of $460,000.
During the six months ended June 30, 1997, the Partnership sold its OEC warrant
for proceeds of $1,000,000 and recognized a gain in the amount of $540,000. At
June 30, 1996, the Partnership recorded its investment in a warrant to purchase
300,000 Cygnus shares (45,000 shares were subsequently exercised and sold by the
Partnership during 1996) at a market value of $15.25 per share as compared to
carrying values of $20.875 and $22.375 per share at March 31, 1996 and December
31, 1995, respectively. Accordingly, the Partnership recognized unrealized
depreciation of $1,687,500 and $2,137,500 for the three months and six months
ended June 30, 1996, respectively. In addition, as of June 30, 1996, the market
value of OEC stock exceeded the exercise price of the Partnership's warrant
resulting in an intrinsic value of $0.925 per share. Accordingly, the
Partnership recognized unrealized appreciation on its warrant in the amount of
$185,000 for the periods ended June 30, 1996.
4. Related Party Transactions
The Manager received an annual management fee for management and
administrative services provided to the Partnership. The management fee was
payable quarterly in advance and was adjusted annually on the first day of each
fiscal year in an amount proportionate to the increase in the prior year in the
Consumer Price Index published by the United States Department of Labor.
Commencing July 1, 1996, the Manager elected to discontinue the management fee
charged to the Partnership. The management fees paid by the Partnership to the
Manager were $68,505 and $137,010 for the three months and six months ended June
30, 1996, respectively.
The money market fund invested in by the Partnership is managed by an
affiliate of PaineWebber Incorporated ("PWI").
9
(Note 4 Continued)
PWDC and PWI, and its affiliates, have acted in an investment banking
capacity for several of the Sponsor Companies. In addition, PWDC and its
affiliates have direct limited partnership interests in some of the same
Projects as the Partnership.
5. Product Development Projects
The Partnership entered into nine Projects (Cayenne Software, Inc.
(formerly Cadre Technologies Inc.); Centocor Partners III, L.P. ("CP III");
Compression Labs, Incorporated; Cygnus; FOCUS Surgery Inc. (formerly Focal
Surgery, Inc.); Genentech Clinical Partners IV, L.P.; Genzyme Development
Partners, L.P.; Rogers Corporation; and Synergen Clinical Partners, L.P.) which
have been fully funded. In addition, the Partnership purchased $5.9 million of
common stock of Alkermes which was distributed to its Partners in 1993 and 1994.
On January 31, 1996, Genzyme Corporation ("Genzyme") made a $93 million
offer (the "Offer") to the general partner of Genzyme Development Partners, L.P.
("GDP") (of which the Partnership owns a limited partnership interest) to
acquire the assets of GDP in exchange for common shares of Genzyme. The Offer
was made in lieu of Genzyme's existing option to purchase the outstanding
partnership interests in GDP for a lump-sum cash payment and certain future
royalty payments. On May 6, 1996, Genzyme withdrew its Offer to purchase the
assets of GDP.
On January 31, 1997, pursuant to the provisions of the Partnership
Purchase Option Agreement between Centocor and the Partnership, Centocor
exercised its option to purchase the limited partnership interests of CP III,
including those owned by the Partnership. The Partnership received an initial
payment and will receive future quarterly payments based on sales of ReoPro, a
drug developed by CP III. For the six months ended June 30, 1997, the
Partnership received and/or accrued income from CP III in the amount of
$5,035,695 which has been included in the accompanying Statements of Operations.
If the Projects produce any product for commercial sale, the Sponsor
Companies have the option to enter into joint ventures or royalty agreements
with the Partnership to manufacture and market the products developed. In
addition, the Sponsor Companies have the option to purchase the Partnership's
interest in the technology. In consideration for such purchase options, the
Partnership has received warrants to purchase shares of common stock of the
Sponsor Companies.
At June 30, 1997, the Partnership owned a warrant to purchase 255,000
shares of Cygnus at an exercise price of $9.90 per share with an excercise
period expiring in September 1997. Since the market price per share at June 30,
1997, of $17.25 exceeded the exercise price per share the Partnership has
recorded this investment at its intrinsic value which approximates fair value
(see Note 3). The Partnership's warrant to purchase 193,000 shares of
Cayenne Software, Inc. at an exercise price of $16.19 per share expired in
June 1997. The Partnership did not exercise the warrant since the market price
of the stock never exceeded the exercise price of the warrant.
6. Income Taxes
The Partnership is not subject to federal, state or local income taxes.
Accordingly, the individual Partners are required to report their distributive
shares of realized income and loss on their individual federal and state income
tax returns.
10
7. Legal Proceeding
On July 12, 1995, the Partnership commenced a derivative action against
Centocor and Centocor Development Corporation III ("CDC III") in the Chancery
Court of Delaware (the "Court") arising from certain agreements entered into by
Centocor and Eli Lilly & Company ("Lilly") in July 1992. The Partnership's
complaint alleges, among other things that: at least $25 million of the $100
million paid by Lilly to Centocor represents profits from the sale of ReoPro, a
Centocor drug, that Centocor is required to share with CP III; and because of
the Lilly transaction, Centocor was required to increase the percentages of
profits and revenues from ReoPro that it pays to CP III investors. Centocor had
taken the position that only $500,000 of the $100 million had to be shared with
CP III and that Centocor had no obligation to increase the percentages of ReoPro
profits and revenues that it pays to CP III investors. The Partnership sought to
proceed on behalf of CP III. The complaint seeks to require Centocor and CDC III
to pay damages to CP III and to increase the percentages of future ReoPro
profits and revenues that Centocor must pay to CP III and its investors.
Centocor answered the Partnership's complaint, as well as a similar
complaint filed by John E. Abdo, another limited partner of CP III, denying the
material allegations of those complaints and asserting purported affirmative
defenses and third-party claims against PWG, PWDC and PWI.
In April and July 1996, Mr. Abdo moved to amend his complaint to assert
claims on behalf of CP III against two of PWDC's nominees to the CDC III Board
of Directors. On July 12, 1996, counsel chosen by Centocor to represent CP III
moved to disqualify the Partnership from serving as a plaintiff in this action,
alleging that Mr. Abdo should by the sole plaintiff because the Partnership has
conflicts of interest with CP III and its other limited partners, including
conflicts arising out of the alleged claims against the PWDC nominees. Mr. Abdo
and Centocor also moved to disqualify the Partnership. In January 1997, the
Court granted, in part, Mr. Abdo's motion to amend his complaint to assert
claims against the PWDC nominees. The Court has not ruled on the motions to
disqualify.
In June 1997, the parties to the Partnership's action entered into an
agreement to settle the action. The agreement provides, among other things, for
Centocor to pay to CP III investors (including the Partnership, a former limited
partner in CP III) in the aggregate: $10.8 million, net of attorneys' fees and
expenses as may be awarded by the Court; an additional $5.0 million, if and when
cumulative world-wide sales of ReoPro exceed $600 million; and possible
additional payments totaling $2.2 million, depending upon regulatory
developments in Japan.
The agreement further provides for revisions to the ReoPro royalties
payable by Centocor to CP III investors through 2007. Under the agreement, those
royalties would be paid based on revenues from end-sales by Lilly and other
distributors, as opposed to Centocor's revenues on 6.5% of the first sales to
distributors. For 1997 and 1998, Centocor would pay an aggregate of 6.5% of the
first $175 million of United States end-sale revenues, 3.25% of such revenues
above $175 million, and 3.25% of foreign end-sales revenues. For 1999 through
2007, Centocor would pay an aggregate of 6.5% of the first $250 million of
United States end-sale revenues, 4% of such revenues above $250 million, and
3.25% of foreign end-sales revenues. Depending upon the future success of
ReoPro, PWDC believes that the adjustments will result in an increase over what
Centocor would have paid in the absence of the litigation and settlement. In any
event, the agreement provides that investors will not receive less than Centocor
would otherwise have paid based on Centocor's sales of ReoPro.
On June 27, 1997, the Court entered an order: preliminarily approving the
settlement; providing for notice to a class consisting of all holders of CP III
Class A and C limited partnership interests as of the
11
(Note 7 Continued)
close of business on January 31, 1997, and all holders of CP III Class B limited
partnership interests as of the close of business on May 31, 1997, and their
transferees, successors, and assigns, other than defendants; and designating the
Partnership's counsel as counsel for the class. The Court also scheduled a
hearing for September 4, 1997, to determine whether the proposed settlement
should be approved.
Mr. Abdo's counsel has stated that he intends to object to the proposed
settlement because, among other things, it would release alleged claims against
the PWDC nominees.
PWDC has been advancing, and may continue to advance, the funds necessary
to pay the Partnership's legal fees and expenses relating to this litigation. In
the event of a recovery on behalf of CP III, the Court may award legal fees and
expenses to the Partnership's counsel to be paid out of the CP III recovery.
Counsel for the Partnership has stated that they intend to apply to the Court
for an award of fees and expenses in an amount up to $1.5 million. Counsel for
Mr. Abdo has stated that he intends to object to any such application, and, if
the settlement is approved, will himself apply for an award of fees and
expenses. It is anticipated that: the net proceeds of any recovery will be
distributed to the limited partners of CP III, including the Partnership, on a
pro rata basis; the Partnership and/or its counsel will reimburse PWDC; and any
remaining Partnership proceeds will be distributed to the Partners of the
Partnership on a pro rata basis.
8. Subsequent Event
Effective July 21, 1997, the General Partner removed the previously
imposed restrictions on the transferability of Units to permit, subject to the
approval of the General Partner, transfers in addition to those that occur as a
result of the laws of descent and distribution or by operation of law.
12
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
Liquidity and Capital Resources
Partners' capital increased from $3.1 million at December 31, 1996, to
$3.9 million at June 30, 1997, resulting from the recognition of income of $6.2
million for the six months ended June 30, 1997 (as more fully explained in
Results of Operations below) offset by cash distributions to the Partners of
$5.4 million.
The Partnership's working capital is invested in marketable securities and
a money market fund. Liquid assets at June 30, 1997 and December 31, 1996, were
$1.2 million and $0.9 million, respectively. The increase of $0.3 million was
due primarily to proceeds received from a Project of $5.0 million and the sale
of an investment for proceeds of $1.0 million offset by a cash distribution of
$5.4 million and a payment to a Project of $0.3 million. The balance of liquid
assets will be used for the payment of administrative costs related to managing
the Partnership's investments.
Results of Operations
Three months ended June 30, 1997 compared to the three months ended
June 30, 1996:
Net income for the quarter ended June 30, 1997 was $1.6 million as
compared to a net loss of $1.5 million for the quarter ended June 30, 1996. The
favorable variance of $3.1 million resulted from an increase in revenues of $3.0
million and a decrease in expenses of $0.1 million.
Revenues for the quarters ended June 30, 1997 and 1996 were $1.6 million
and $(1.4) million, respectively. The increase of $3.0 million was due primarily
to an increase in unrealized appreciation of investments and marketable
securities of $2.4 million and an increase of $0.5 million in income from
product development projects. Unrealized appreciation (depreciation) of
investments and marketable securities for the quarters ended June 30, 1997 and
1996 was $0.9 million and $(1.5) million, respectively. At June 30, 1997, the
market value per share of Cygnus stock was $17.25 as compared to $13.625 at
March 31, 1997. Accordingly, the Partnership recognized unrealized appreciation
of $0.9 million on its warrant to purchase 255,000 shares. As of June 30, 1996,
the Partnership recognized unrealized depreciation of $1.7 million on its
warrant to purchase 300,000 Cygnus shares to reflect a decrease in market value
from $20.875 per share at March 31, 1996 to $15.25 per share as of June 30,
1996. In addition, as of June 30, 1996, the market price of OEC of $13.625 per
share exceeded the exercise price of the Partnership's warrant to purchase
200,000 OEC shares in the amount of $12.70 per share. The Partnership recorded
the warrant at its intrinsic value of $0.2 million and, accordingly, recognized
unrealized appreciation of this amount. On January 31, 1997, Centocor exercised
its option to purchase the limited partnership interests of CP III (including
those owned by the Partnership) for an initial payment plus the right to receive
quarterly future payments based upon sales of certain products developed by CP
III. For the quarter ended June 30, 1997, the Partnership accrued income due
from CP III in the amount of $0.7 million. For this same period in 1996 the
Partnership accrued income from product development projects of $0.2 million.
The decrease in expenses of $0.1 million was a result of the Manager's
decision to discontinue the management fee charged to the Partnership as of July
1, 1996.
13
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations
Six months ended June 30, 1997 compared to the six months ended June 30, 1996:
Net income (loss) for the six months ended June 30, 1997 and 1996 was $6.2
million and $(2.0) million, respectively. The favorable variance of $8.2 million
resulted in an increase in revenues of $8.1 million and a decrease in expenses
of $0.1 million (see Results of Operations - three months ended June 30, 1997
compared to the three months ended June 30, 1996).
Revenues for the six months ended June 30, 1997 and 1996 were $6.3 million
and $(1.8) million respectively. The increase of $8.1 million was due primarily
to increases of $4.9 million in income from product development projects; $0.6
million in gain on the sale of investments and marketable securities; and
unrealized appreciation of investments of $2.6 million. On January 31, 1997,
Centocor exercised its option to purchase the limited partnership interests of
CP III (including those owned by the Partnership). The Partnership received an
initial payment and the right to receive future payments based upon sales of
certain products developed by CP III. For the six months ended June 30, 1997,
the Partnership received and/or accrued income due in connection with its
investment in CP III of $5.1 million. During the same period in 1996 the
Partnership accrued income from product development projects of $0.2 million.
During the six months ended June 30, 1997, the Partnership sold its warrant to
purchase 200,000 shares of OEC for proceeds of $1.0 million and recognized a
gain of $0.5 million from the sale. Unrealized appreciation (depreciation) of
investments and marketable securities for the six months ended June 30, 1997 and
1996 was $0.7 million and $(1.9) million, respectively. For the six months ended
June 30, 1997, the Partnership recognized unrealized appreciation of $0.7
million with respect to its warrant to purchase 255,000 common shares of Cygnus.
The market value of the shares increased from $14.50 per share as of December
31, 1996 to $17.25 per share at June 30, 1997. As of June 30, 1996, the
Partnership recognized unrealized depreciation of $2.1 million on its warrant to
purchase 300,000 Cygnus shares to reflect a decrease in the market value per
share of Cygnus stock from $22.375 at December 31, 1995 to $15.25 at June 30,
1996. In addition the Partnership recognized unrealized appreciation of $0.2
million on its warrant to purchase OEC shares.
14
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
Action Against Centocor, Inc. and Centocor Development
Corporation III
Information regarding this action was disclosed on the
Partnership's Form 10-K for the year ended December 31, 1996 and the
Partnership's Form 10-Q for the quarter ended March 31, 1997. In
June 1997, the parties to the Partnership's action entered into an
agreement to settle the action. The agreement provides, among other
things, for Centocor to pay to CP III investors (including the
Partnership, a former limited partner in CP III) in the aggregate:
$10.8 million, net of attorneys' fees and expenses as may be awarded
by the Court; an additional $5.0 million, if and when cumulative
world-wide sales of ReoPro exceed $600 million; and possible
additional payments totaling $2.2 million, depending upon regulatory
developments in Japan.
The agreement further provides for revisions to the ReoPro
royalties payable by Centocor to CP III investors through 2007.
Under the agreement, those royalties would be paid based on revenues
from end-sales by Lilly and other distributors, as opposed to
Centocor's revenues on its sales to distributors. For 1997 and 1998,
Centocor would pay an aggregate of 6.5% of the first $175 million,
of United States end-sale revenues, 3.25% of such revenues above
$175 million, and 3.25% of foreign end-sales revenues. For 1999
through 2007, Centocor would pay an aggregate of 6.5% of the first
$250 million of United States end-sale revenues, 4% of such
revenues above $250 million and 3.25% of foreign end-sales
revenues. Depending upon the future success of ReoPro, PWDC
believes that the adjustments will result in an increase over what
Centocor would have paid in the absence of the litigation and
settlement. In any event, the agreement provides that investors
will not receive less than Centocor would otherwise have paid
based on Centocor's sales of ReoPro.
On June 27, 1997, the Court entered an order: preliminarily
approving the settlement; providing for notice to a class consisting
of all holders of CP III Class A and C limited partnership interests
as of the close of business on January 31, 1997, and all holders of
CP III Class B limited partnership interests as of the close of
business on May 31, 1997, and their transferees, successors, and
assigns, other than defendants; and designating the Partnership's
counsel as counsel for the class. The Court also scheduled a hearing
for September 4, 1997, to determine whether the proposed settlement
should be approved.
Counsel for John E. Abdo, another limited partner of CP III,
has stated that he intends to object to the proposed settlement
because, among other things, it would release alleged claims against
the PWDC nominees.
In re: PaineWebber Partnership Litigation
Information regarding this action was disclosed on the
Partnership's Form 10-K for the year ended December 31, 1996 and the
Partnership's Form 10-Q for the quarter ended March 31, 1997.
Action Against Amgen Boulder, Inc.
Information regarding this action was disclosed on the
Partnership's Form 10-K for the year ended December 31, 1996 and the
Partnership's Form 10-Q for the quarter ended March 31, 1997. In
February 1997, the parties announced a proposed settlement of this
action, pursuant to which the defendants would pay $14,550,000, less
attorney's fees and costs, to class members, and the limited
partners' interests in Synergen Clinical Partners, L.P. ("SCP")
would
15
Item 1. Legal Proceedings
be terminated. The settlement was conditioned on, among other things,
the approval of two-thirds of the current limited partnership
interests in SCP and final court approval. The General Partner
concluded that the proposed settlement was inadequate and not in the
best interests of the Partnership. Accordingly, the General Partner,
on behalf of the Partnership, objected to the proposed settlement.
On June 19, 1997, the parties and the General Partner advised
the Court that they had reached an agreement in principle to
supplement the proposed settlement and to resolve the Partnership's
objection. The agreement in principle was subject to final
documentation. The court ordered that such documentation be filed by
July 3, 1997. On July 3, 1997, the parties informed the court that
they had been unable to reach agreement on final documentation.
Item 6. Exhibits and Reports on Form 8-K.
a) Exhibits:
None
b) Reports on Form 8-K:
On July 29, 1997 the Partnership filed a current report on Form
8-K relating to the General Partner's removal of the restrictions on
the transferability of Units to permit, subject to the approval of
the General Partner, transfers in additions to those that occur as a
result of the laws of descent and distribution on by operation of
law.
16
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on this 14th day of
August 1997.
PAINEWEBBER R&D PARTNERS II, L.P.
By: PaineWebber Technologies II, L.P.
(General Partner)
By: PWDC Holding Company
(general partner of the General Partner)
By: Dhananjay M. Pai/s/
------------------
Dhananjay M. Pai
President*
By: Anthony M. DiIorio/s/
--------------------
Anthony M. DiIorio
Principal Financial and Accounting Officer*
17
* The capacities listed are with respect to PWDC Holding Company, the Manager,
as well as PWDC, the parent company of the Manager.
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, on this 14th day of
August 1997.
PAINEWEBBER R&D PARTNERS II, L.P.
By: PaineWebber Technologies II, L.P.
(General Partner)
By: PWDC Holding Company
(general partner of the General Partner)
By: Dhananjay M. Pai/s/
------------------
Dhananjay M. Pai
President*
By: Anthony M. DiIorio/s/
--------------------
Anthony M. DiIorio
Principal Financial and Accounting Officer*
* The capacities listed are with respect to PWDC Holding Company, the Manager,
as well as PWDC, the parent company of the Manager.
17